Flinton Capital Management LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 97.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,992 shares of the biotechnology company’s stock after buying an additional 5,424 shares during the quarter. Flinton Capital Management LLC’s holdings in Biogen were worth $2,983,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Prudential PLC lifted its position in Biogen by 60.8% during the 2nd quarter. Prudential PLC now owns 111,743 shares of the biotechnology company’s stock worth $30,322,000 after buying an additional 42,258 shares in the last quarter. Samlyn Capital LLC lifted its position in Biogen by 64.4% during the 2nd quarter. Samlyn Capital LLC now owns 710,500 shares of the biotechnology company’s stock worth $192,801,000 after buying an additional 278,400 shares in the last quarter. AHL Partners LLP lifted its position in Biogen by 116.9% during the 2nd quarter. AHL Partners LLP now owns 17,647 shares of the biotechnology company’s stock worth $4,789,000 after buying an additional 9,511 shares in the last quarter. Boston Common Asset Management LLC lifted its position in Biogen by 15.8% during the 2nd quarter. Boston Common Asset Management LLC now owns 27,193 shares of the biotechnology company’s stock worth $7,379,000 after buying an additional 3,707 shares in the last quarter. Finally, Sun Life Financial INC lifted its position in Biogen by 586.4% during the 2nd quarter. Sun Life Financial INC now owns 3,034 shares of the biotechnology company’s stock worth $823,000 after buying an additional 2,592 shares in the last quarter. 87.65% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Biogen Inc. (BIIB) traded up 3.38% on Thursday, hitting $325.57. 757,059 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $309.33 and its 200 day moving average is $280.58. The firm has a market cap of $68.84 billion, a P/E ratio of 21.36 and a beta of 0.77. Biogen Inc. has a 12 month low of $244.28 and a 12 month high of $330.98.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share for the quarter, topping the consensus estimate of $4.36 by $0.68. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $2.81 billion. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the company earned $5.21 earnings per share. On average, equities analysts predict that Biogen Inc. will post $21.51 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Flinton Capital Management LLC Has $2.98 Million Holdings in Biogen Inc. (BIIB)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/flinton-capital-management-llc-has-2-98-million-holdings-in-biogen-inc-biib/1610405.html.

BIIB has been the topic of several analyst reports. Vetr cut shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price target on the stock. in a research report on Tuesday, August 29th. ValuEngine raised shares of Biogen from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Cowen and Company reissued an “outperform” rating and set a $271.00 price target on shares of Biogen in a research report on Monday, July 3rd. William Blair reissued an “outperform” rating on shares of Biogen in a research report on Monday, June 26th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $310.00 price target on shares of Biogen in a research report on Tuesday, July 11th. Thirteen research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Biogen has a consensus rating of “Buy” and a consensus price target of $330.83.

In related news, EVP Susan H. Alexander sold 7,758 shares of the business’s stock in a transaction that occurred on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total transaction of $2,211,030.00. Following the completion of the transaction, the executive vice president now owns 27,232 shares of the company’s stock, valued at $7,761,120. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Susan H. Alexander sold 4,974 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the transaction, the executive vice president now directly owns 22,258 shares of the company’s stock, valued at approximately $6,455,042.58. The disclosure for this sale can be found here. 0.25% of the stock is owned by company insiders.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.